Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MM-302 + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MM-302 | MM302|Gancotamab | HER2 (ERBB2) Antibody 76 | MM-302 (Gancotamab) is a liposome containing doxorubicin and conjugated to a monoclonal antibody against the ERBB2 (HER2) receptor, which improves efficacy while reducing toxicity (PMID: 27259714, PMID: 30361524). | |
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02213744 | Phase II | Trastuzumab + Vinorelbine Capecitabine + Trastuzumab Gemcitabine + Trastuzumab MM-302 + Trastuzumab | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 1 |